Owing to the problems with bacterial L-asparaginases, new agents that could induce apoptosis of L-asparagine-dependent tumor cells would be of major interest.
Depletion of L-asparagine supply and apoptosis of leukemia cells induced by human glycosylasparaginase
L-Asparaginase (ASNase; EC 3.5.1.1) is widely used in the treatment of acute lymphoblastic leukemia in combination with other anticancer drugs. The administration of L-asparaginase is followed by a rapid depletion of the L-asparagine concentration in plasma owing to its hydrolysis to L-aspartic acid and ammonia. Certain tumor cells, which lack or have a reduced level of L-asparagine synthetase, are dependent on their external supply of L-asparagine. Depletion of this supply by L-asparaginase suppresses the growth and development of the cells and induces their apoptosis.
1 Serious side effects associated with the L-asparaginase therapy, including the development of antibodies against the bacterial proteins foreign to the human body, drug resistance and disturbance of the L-glutamine metabolism of various tissues owing to the L-glutaminase activity of the L-asparaginases, 2 have been related to the use of bacterial L-asparaginases. Owing to the problems with bacterial L-asparaginases, new agents that could induce apoptosis of L-asparagine-dependent tumor cells would be of major interest.
A lysosomal enzyme glycosylasparaginase (GA; aspartylglucosaminidase; EC 3.5.1.26) hydrolyzes the N-glycosidic carbohydrate-to-protein linkage region, aspartylglucosamine, to L-aspartic acid and l-amino-N-acetylglucosamine through a reaction mechanism similar to L-asparaginase. 3 Glycosylasparaginase is transported in active form into various non-neuronal cell types, including Epstein-Barr virus-transformed (EBV) glycosylasparaginase-deficient lymphoblasts, and it effectively corrects the metabolic defects in glycosylasparaginase-deficient cell lines 4 and mice. 5 The finding that human glycosylasparaginase also hydrolyzes L-asparagine to L-aspartic acid and ammonia-like bacterial L-asparaginases 6 without any L-glutaminase activity 3 led us to investigate its potential cytotoxic activity toward leukemia cells that are dependent on their external supply of L-asparagine.
We investigated the ability of human recombinant GA to deplete the intra-and extracellular Asn reservoirs in vitro using EBVtransformed glycosylasparaginase-deficient lymphoblasts from an aspartylglycosaminuria patient. 4 Lymphoblasts were continuously grown in an RPMI-1640 (HyClone, Logan, Utah, USA) medium supplemented with 15% of fetal calf serum (BioClear, Wiltshire, UK), 2 mM L-glutamine (HyClone) and 1.5-2.0 mM L-asparagine (Fluka Chemie AG, Buchs, Switzerland) and various concentrations of either GA or Erwinia L-asparaginase (Erwinase, ErAII) for 24 h. The kinetic parameters of the enzymes for the hydrolysis of L-asparagine were determined by a spectrophotometric method as described. 7, 8 At pH 7.5, the K m of glycosylasparaginase, Erwinia L-asparaginase and Escherichia coli L-asparaginase was 538, 90 and 130 mM and V max 1.49, 16 and 23 mM/min, respectively. One unit of enzyme causes hydrolysis of 1 mmol of L-asparagine per minute under standard conditions. The depletion of the extracellular Asn concentration in the culture medium from 2.3 to 0.2 mmol/l in the presence of 10 or 40 U/l of glycosylasparaginase or 10 U/l of ErAII took 18, 4 and 4 h, respectively. In the presence of 1500 U/l of ErAII, similar Asn concentration decrease occurred within 5 min. The Asn level in the cell culture medium remained unchanged at approximately 2 mmol/l in the absence of either glycosylasparaginase or ErAII (Figure 1a) .
To determine whether the enzymes can deplete the intracellular Asn reservoirs of EBV-transformed lymphoblasts, we analyzed both the Asn concentration and the enzyme activity inside the cells during the incubation. In the presence of 10 or 40 U/l of glycosylasparaginase or 10 U/l of ErAII in the cell culture medium, the Asn concentration inside the GA-deficient cells first increased within the first 2 h of incubation from the initial approximately 80 nmol/mg protein and then decreased below 6 nmol/mg protein during the next 16-18, 6 or 10-12 h, respectively ( Figure 1b ). In the presence of 1500 U/l of ErAII in the culture medium, the intracellular Asn concentration decreased from 89 to 14 nmol/mg protein within 1 min. In the absence of either enzyme, the Asn level inside the cells increased during the first 4-6 h and then stabilized around 100 nmol/mg protein during the next 18-20 h of incubation ( Figure 1b) .
The activity of GA and ErAII appeared in the lymphoblasts within 5-15 min, reached the peak value 1-2 h later and then decreased gradually during the next 24 h after their addition into the culture medium ( Figure 1c ). The higher the activity of the enzymes was in the culture medium, the higher was their activity in the lymphoblasts. In the absence of the enzymes, the Lasparaginase activity remained at the zero level both in the culture medium and in the lymphoblast samples (Figure 1c ). The combined evidence shows that GA and ErAII deplete the extraand intracellular L-asparagine reservoirs of EBV-transformed glycosylasparaginase-deficient lymphoblasts in a comparable and dose-dependent manner. Earlier studies have shown that GA is actively transported into glycosylasparaginase-deficient lymphoblasts, in which it locates mostly in the cytoplasm and lysosomes. 4 The location of ErAII in the lymphoblasts was not studied in this work. In theory, the observed L-asparaginase activity in lysed lymphoblasts could result from ErAII attached to the cell membrane or from enzyme that has entered the cells, or both.
The above mentioned results, along with our earlier results that enzyme replacement therapy with glycosylasparaginase effectively removes the lysosomal storage of GlcNAc-Asn from glycosylasparaginase-deficient cell lines 4 and mice, 5 led us to consider GA as a potential cytotoxic enzyme against L-asparagine-dependent leukemia cells. We supplemented the culture medium of two different leukemic cell lines, human B-cell precursor leukemia SUP-B15 cells and human T-lineage leukemia CCRF-CEM cells, either with GA, dephosphorylated ErAII 1500 U/l (K) into the culture medium, or in the absence of enzymes (n). Aliquots of the culture mixture were removed periodically, kept on ice and centrifuged (220 g, 5 min at 4 1C). The medium was separated and stored at À20 1C until assay. The pelleted cells were washed twice with ice-cold phosphate-buffered saline (PBS) and then lysed in 50 mM sodium-potassium phosphate buffer, pH 7.5, through three freezing-thawing cycles and sonication in an ice bath for 30 s. The enzyme activity was measured by a fluorometric assay 4 and the Asn concentration was analyzed with high-performance liquid chromatography.
GA or two bacterial L-asparaginases used in chemotherapy, Erwinase s (ErAII) and Elspar s (E. coli L-asparaginase, EcAII). The sensitivity of the cells to each enzyme was tested with the MTT assay. 9 The dephosphorylated GA, which possesses normal enzyme activity but enters the NIH-3T3 cells less effectively than does phosphorylated GA, 4 was used to figure out whether there was any difference between the native phosphorylated and dephosphorylated GA in inducing the death of the leukemic cells. The enzyme concentrations that caused a 50% growth inhibition of SUP-B15 cells (IC 50 values) in cell culture for GA, dephosphorylated GA, ErAII and EcAII were 15, 16, 8 and 5 U/l, respectively (Figure 2a) . After 72 h exposure to 1000 U/l of any of the four enzymes, the proportion of the viable SUP-B15 cells was approximately 20%. The results show that GA and dephosphorylated GA induce the death of human B-cell precursor leukemia (SUP-B15) with an efficacy comparable to that of bacterial L-asparaginases (Figure 2a) .
The T-lymphoblastoid CCRF-CEM cell line was less sensitive to all of the enzymes. After 96 h incubation in the presence of 100 U/l of dephosphorylated GA or GA, the viability of the CCRF-CEM cells was 60 or 70%, respectively (Figure 2b) . A dose-dependent growth inhibition could be shown with each enzyme among human T-cell leukemia CCRF-CEM cells, but it was less effective with GA than with ErAII and EcAII (Figure 2b) . The IC 50 values for ErAII and EcAII were 800 and 1100 U/l, respectively.
We examined the late event of apoptosis, DNA fragmentation, at a single cell level with the TUNEL (TdT-mediated dUTP nick end labeling) method. The SUP-B15 cells were incubated for 2 days at 37 1C in the presence of 100 U/l of dephosphorylated GA and then stained with tetramethylrhodamine and 4,6-diamidino-2-phenylindole. The evaluation of the cells under fluorescence microscopy showed that most of the cells incubated with dephosphorylated GA were apoptotic (data not shown).
To evaluate the proportion of apoptotic cells in the SUP-B15 cell population after incubation for 2 days at 37 1C in the presence of phosphate-buffered saline, dephosphorylated GA or ErAII, the tetramethylrhodamine-stained cells were analyzed by a flow cytometer. As a positive control, we used SUP-B15 cells, which were incubated in phosphate-buffered saline at 37 1C for 2 days, and which, after fixation and permeabilization, incubated with DNase I (1 mg/ml) for 10 min at room temperature to induce DNA strand breaks and finally stained with tetramethylrhodamine. The proportion of the apoptotic cells in the SUP-B15 cell population after an incubation in the presence of either phosphate-buffered saline, phosphatebuffered saline þ DNase, 100 U/l dephosphorylated GA or 1 000 000 U/l ErAII (positive control) was 28, 90, 65 and 69%, respectively ( Figure 3-region A) .
The combined evidence clearly shows the proof-of-principle that glycosylasparaginase could replace bacterial L-asparaginases in depletion of L-asparagine supply and induction of apoptosis of L-asparagine-dependent tumor cells. Our results with glycosylasparaginase-deficient lymphoblasts show that glycosylasparaginase and Erwinase s are equally effective in depleting the L-asparagine reservoirs both inside and outside of the cells in vitro. The phenomenon is dose-dependent: the higher the enzymes activity in the culture medium, the faster the depletion of the extra-and intracellular L-asparagine stores.
Supplementation of the culture medium of L-asparaginedependent human B-cell precursor leukemia SUP-B15 cells either with glycosylasparaginase or dephosphorylated glycosylasparaginase induced the death of the cells by apoptosis as effectively as did the clinically used L-asparaginases, Erwinase s and Elspar s . All the enzymes were less effective in inducing the death of CCRF-CEM cells. This is in line with earlier studies,that have shown that CCRF-CEM cells are poorly sensitive 10 and SUP-B15 cells highly sensitive 11 to L-asparaginase therapy. Our results show that this applies to glycosylasparaginase therapy in vitro as well.
Dephosphorylation of the mannose-6-phosphate residues of GA does not seem to affect the activity or ability of the enzyme to induce apoptosis in the Asn-dependent leukemia cells, although it reduces the transport of the enzyme into cells through the mannose-6-phosphate-receptor-dependent transport system. 4 The equal efficacy of phosphorylated and dephosphorylated GA in induction of apoptosis of Asn-dependent leukemia cells may indicate either the importance of degradation of extracellular Asn stores by dephosphorylated GA in the apoptosis of cells or the presence of other, mannose-6-phosphate-independent mechanisms for GA to enter the cells. An important extracellular source of L-asparagine for acute lymphoblastic leukemia blasts includes bone marrow mesenchymal cells, which excrete and increase L-asparagine concentration in the leukemic cell microenvironment and cause resistance to bacterial L-asparaginase therapy. 12 Whether the administration of glycosylasparaginase in vivo will effectively correct these changes in the tumor cell microenvironment will be important for study. Interestingly, enzyme replacement therapy with glycosylasparaginase effectively clears non-neuronal tissues from lysosomal storage of glycoasparagines typical of glycosylasparaginase-deficient mice. 5 From the therapeutic point of view, the administration of glycosylasparaginaseFan endogenous human protein with no L-glutaminase activity 3 Fmight cause fewer side effects to the human body than that of bacterial L-asparaginases. Thus, the combined evidence shown above and the serious side effects associated with L-asparaginase therapy using bacterial L-asparaginases suggest that the applicability of human glycosylasparaginase as a potential anticancer agent to induce apoptosis in L-asparagine-dependent cancer cells should be studied further. 
